Newsroom

 Press Release
  • Momentum Builds for Congress to Stop Big Pharma’s Costly Patent Abuse

    April 17, 2026
  • PCMA Urges Congress to Promote Competition by Addressing Patent Abuse, Reining In Big Pharma’s DT...

    April 16, 2026
  • PCMA Calls on DOL to Protect Competition in the PBM Market, Rescind Duplicative Proposed Rule

    April 15, 2026

with Amanda Frost

Innovation That Puts Patients First

Every year, like clockwork, drug prices go up. For many patients, those increases aren’t just numbers on a chart; they’re real barriers to getting the care they need. That’s where pharmacy benefit managers (PBMs) come in, helping to mitigate the financial pressures and barriers to access that come with high drug prices.

Read More »

Greg Lopes

Vice President,
Public Affairs

glopes@pcmanet.org
202-756-5713

Federal Regulatory Comment Letters

The Federal Regulatory Comment Letters section houses PCMA’s formal public responses to proposed federal regulations and rulemakings that affect pharmacy benefit managers (PBMs) and broader health care policy.